2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.
2-HG
AML
diagnosis
therapy
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
09 Jun 2022
09 Jun 2022
Historique:
received:
29
04
2022
revised:
31
05
2022
accepted:
02
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The oncometabolite 2-hydroxyglutarate (2-HG) plays a key role in differentiation blockade and metabolic reprogramming of cancer cells. Approximatively 20-30% of acute myeloid leukemia (AML) cases carry mutations in the isocitrate dehydrogenase (IDH) enzymes, leading to a reduction in the Krebs cycle intermediate α-ketoglutarate (α-KG) to 2-HG. Relapse and chemoresistance of AML blasts following initial good response to standard therapy account for the very poor outcome of this pathology, which represents a great challenge for hematologists. The decrease of 2-HG levels through pharmacological inhibition of mutated IDH enzymes induces the differentiation of AML blasts and sensitizes leukemic cells to several anticancer drugs. In this review, we provide an overview of the main genetic mutations in AML, with a focus on IDH mutants and the role of 2-HG in AML pathogenesis. Moreover, we discuss the impact of high levels of 2-HG on the response of AML cells to antileukemic therapies and recent evidence for highly efficient combinations of mutant IDH inhibitors with other drugs for the management of relapsed/refractory (R/R) AML.
Identifiants
pubmed: 35740380
pii: biomedicines10061359
doi: 10.3390/biomedicines10061359
pmc: PMC9220225
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
EMBO J. 2000 Aug 15;19(16):4298-309
pubmed: 10944113
J Exp Med. 2010 Feb 15;207(2):339-44
pubmed: 20142433
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Blood. 2010 Dec 16;116(25):5486-96
pubmed: 20805365
Cancer Cell. 2010 Mar 16;17(3):225-34
pubmed: 20171147
Cancer. 2019 Feb 15;125(4):541-549
pubmed: 30422308
Cell. 2021 Apr 15;184(8):2256
pubmed: 33861966
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Leukemia. 1987 Aug;1(8):580-3
pubmed: 3669771
Leukemia. 2011 Oct;25(10):1570-7
pubmed: 21647154
Cancer Discov. 2019 Jul;9(7):910-925
pubmed: 31048320
Nat Med. 2015 Feb;21(2):178-84
pubmed: 25599133
JAMA Oncol. 2018 Aug 1;4(8):1106-1110
pubmed: 29346478
Cell Stem Cell. 2014 Mar 6;14(3):329-41
pubmed: 24440599
Blood Adv. 2020 May 12;4(9):1894-1905
pubmed: 32380538
Nature. 2017 Aug 10;548(7666):228-233
pubmed: 28783731
Front Oncol. 2021 Mar 11;11:649209
pubmed: 33777810
Cancer Discov. 2018 Dec;8(12):1540-1547
pubmed: 30355724
Am J Blood Res. 2012;2(4):254-64
pubmed: 23226625
Oxid Med Cell Longev. 2019 Dec 3;2019:9474823
pubmed: 31885826
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Science. 2013 Mar 29;339(6127):1621-5
pubmed: 23393090
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Am J Hematol. 2021 Apr 1;96(4):493-507
pubmed: 33368536
Leukemia. 2017 Oct;31(10):2020-2028
pubmed: 28232670
Ann Intern Med. 1992 Aug 15;117(4):292-6
pubmed: 1637024
Blood Adv. 2021 Jan 12;5(1):156-166
pubmed: 33570627
EMBO Rep. 2011 May;12(5):463-9
pubmed: 21460794
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
J Cancer. 2019 Aug 27;10(20):4824-4835
pubmed: 31598153
Pediatr Blood Cancer. 2013 May;60(5):728-33
pubmed: 23303597
Crit Rev Oncol Hematol. 2017 Feb;110:20-34
pubmed: 28109402
Oncogene. 2001 Oct 29;20(49):7140-5
pubmed: 11704842
Nature. 2012 Feb 15;483(7390):484-8
pubmed: 22343896
J Clin Oncol. 2019 May 20;37(15):1277-1284
pubmed: 30892988
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5
pubmed: 27245312
J Inherit Metab Dis. 2006 Feb;29(1):21-9
pubmed: 16601864
Clin Cancer Res. 2017 Aug 1;23(15):4511-4522
pubmed: 28246275
Front Oncol. 2013 Jul 02;3:169
pubmed: 23847760
Metabolomics. 2020 Jan 10;16(1):13
pubmed: 31925544
Br J Cancer. 2020 Jan;122(2):168-181
pubmed: 31819197
Front Pediatr. 2021 Apr 23;9:639479
pubmed: 33968846
J Exp Med. 2011 Jul 4;208(7):1367-76
pubmed: 21708926
Biochemistry. 2011 May 31;50(21):4804-12
pubmed: 21524095
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
N Engl J Med. 2022 Apr 21;386(16):1519-1531
pubmed: 35443108
Eur J Cancer. 2012 Nov;48(17):3257-66
pubmed: 22770878
ACS Med Chem Lett. 2020 Jan 22;11(2):101-107
pubmed: 32071674
Cancer Cell. 2015 Dec 14;28(6):773-784
pubmed: 26678339
Science. 2013 May 3;340(6132):626-30
pubmed: 23558169
Blood. 2013 Jun 6;121(23):4769-77
pubmed: 23632886
Blood. 2011 Jul 14;118(2):409-12
pubmed: 21596855
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Leukemia. 2020 Nov;34(11):2903-2913
pubmed: 32733012
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
J Clin Oncol. 2014 Feb 1;32(4):297-305
pubmed: 24344214
Blood. 2013 Jun 13;121(24):4917-24
pubmed: 23641016
J Clin Oncol. 2014 Mar 10;32(8):783-90
pubmed: 24516018
Blood. 2012 Nov 29;120(23):4649-52
pubmed: 23074281
Nature. 2009 Apr 9;458(7239):776-9
pubmed: 19169242
Antioxid Redox Signal. 2020 Nov 1;33(13):903-926
pubmed: 31847543
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Acta Neuropathol. 2010 Apr;119(4):487-94
pubmed: 20127344
Oncoimmunology. 2018 Mar 26;7(7):e1445454
pubmed: 29900057
Blood. 2021 Apr 1;137(13):1792-1803
pubmed: 33024987
Front Oncol. 2017 Jun 09;7:117
pubmed: 28649560
Cancers (Basel). 2022 Jan 26;14(3):
pubmed: 35158884
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17017-22
pubmed: 24082129
ACS Med Chem Lett. 2012 Sep 17;3(10):850-5
pubmed: 24900389
Blood Cancer J. 2022 Jan 25;12(1):10
pubmed: 35078972
Leuk Res. 2021 Dec;111:106727
pubmed: 34700049
Eur J Haematol. 2022 Jul;109(1):58-68
pubmed: 35298049
Free Radic Biol Med. 2016 Nov;100:14-31
pubmed: 27085844
Ann Oncol. 2020 Jun;31(6):697-712
pubmed: 32171751
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Cell Metab. 2013 Nov 5;18(5):698-711
pubmed: 24206664
Nature. 2012 Aug 30;488(7413):656-9
pubmed: 22763442
J Clin Oncol. 2010 May 10;28(14):2348-55
pubmed: 20368543
J Biol Chem. 1993 Jun 5;268(16):12116-22
pubmed: 8099357
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Leukemia. 2017 Feb;31(2):272-281
pubmed: 27721426
Cancer Discov. 2017 May;7(5):478-493
pubmed: 28193778
Genes Dev. 2013 Sep 15;27(18):1974-85
pubmed: 24065765
Blood. 2010 Apr 8;115(14):2749-54
pubmed: 20097881
Blood. 2010 Oct 14;116(15):2779-82
pubmed: 20651067
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
Sci Rep. 2016 Aug 31;6:32428
pubmed: 27577048
Nat Med. 2018 Aug;24(8):1167-1177
pubmed: 30013198
Clin Cancer Res. 2020 Aug 15;26(16):4280-4288
pubmed: 32393603
Cell Rep. 2017 Apr 11;19(2):389-400
pubmed: 28402860
Science. 2009 Apr 10;324(5924):261-5
pubmed: 19359588
Leukemia. 2016 Apr;30(4):782-8
pubmed: 26582645
Annu Rev Biochem. 2017 Jun 20;86:305-331
pubmed: 28375741
Biochem J. 2000 Jun 15;348 Pt 3:607-14
pubmed: 10839993
Exp Hematol Oncol. 2021 Jan 4;10(1):1
pubmed: 33397455
J Clin Oncol. 2010 Aug 1;28(22):3636-43
pubmed: 20567020
N Engl J Med. 2005 Jan 20;352(3):254-66
pubmed: 15659725
ACS Med Chem Lett. 2018 Jan 19;9(4):300-305
pubmed: 29670690
Science. 2013 May 3;340(6132):622-6
pubmed: 23558173
Lancet Oncol. 2021 Nov;22(11):1597-1608
pubmed: 34672961
J Clin Oncol. 2010 Aug 10;28(23):3717-23
pubmed: 20625116
Leukemia. 2017 Nov;31(11):2526-2529
pubmed: 28751773
Cell Death Dis. 2019 Oct 7;10(10):755
pubmed: 31591388
Blood Adv. 2020 Aug 11;4(15):3528-3549
pubmed: 32761235
J Exp Med. 2021 May 3;218(5):
pubmed: 33760042
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Biochem Pharmacol. 2001 Apr 15;61(8):1033-40
pubmed: 11286995
Nat Commun. 2016 Sep 14;7:12700
pubmed: 27624942
J Clin Oncol. 2008 Oct 1;26(28):4603-9
pubmed: 18559876
Cancers (Basel). 2021 Sep 16;13(18):
pubmed: 34572873
Biochim Biophys Acta. 2002 Jan 2;1586(1):81-91
pubmed: 11781152
Haematologica. 2021 Feb 01;106(2):565-573
pubmed: 32241846
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Leukemia. 2011 Feb;25(2):246-53
pubmed: 21079611
Yonsei Med J. 2020 Sep;61(9):762-773
pubmed: 32882760